ClinicalTrials.gg
CompletedNCT02748057Updated May 16, 2024Results posted

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

A Phase 3 interventional study of Ezetimibe and Rosuvastatin in Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
54th of 97
135 · median 148
Started
2016
with 3 others
Phase 3
50 of 98
1 open now
Registered
77th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 54th largest by enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2016, is one of 50 in phase 3, and was the 77th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Rosuvastatin up to 5 mg.

03

Conditions studied

  • Hypercholesterolemia
  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese
  • Outpatient with hypercholesterolemia
  • Female participant who is of has to agree to remain abstinent or use (or partner use) two acceptable methods of from date of signed to the 14 days after the last dose of study drug
  • Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension (treated or untreated)
  • Uncontrolled type 1 or type 2 diabetes mellitus
  • Homozygous Familial Hypercholesterolemia or has undergone low-density lipoprotein (LDL) apheresis
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
  • Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption
  • History of cancer within the past 5 years (except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)
  • (HIV) positive
  • History of drug/alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy
  • Consumes more than 25 g of alcohol per day
  • Currently following an excessive weight reduction diet
  • Currently engages in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study
  • or intolerance to Ezetimibe or Rosuvastatin
  • Myopathy or rhabdomyolysis with Ezetimibe or any statin
  • Pregnant or lactating
  • Taking any other drugs and/or has taken any investigational drugs within 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Ezetimibe 10 mg + Rosuvastatin 2.5 mg

    1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg

    Drug: Ezetimibe · Drug: Rosuvastatin

  • Experimental
    Ezetimibe 10 mg + Rosuvastatin 5.0 mg

    1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.

    Drug: Ezetimibe · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experience at Least 1 Adverse Event (AE)

    An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who reported at least 1 AE was summarized.

    Time frame: Up to 2 weeks post last dose of study drug (up to 54 weeks)

  2. Percentage of Participants Who Had Study Drug Discontinued Due to an AE

    An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who had study drug discontinued due to an AE was summarized.

    Time frame: up to 52 weeks

Secondary outcomes

  1. Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

    Blood was collected at baseline (predose) and after 52 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by beta quantification ultracentrifugation. The percentage change from baseline at Week 52 was summarized.

    Time frame: Baseline (predose) and Week 52

07

Results

Posted Dec 4, 2018

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mg
Started11421
Completed10919
Not completed52
Withdrew: Adverse event10
Withdrew: Physician decision01
Withdrew: Protocol violation21
Withdrew: Participant moved10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants Who Experience at Least 1 Adverse Event (AE)

An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who reported at least 1 AE was summarized.

Time frame:
Up to 2 weeks post last dose of study drug (up to 54 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
Percentage of ParticipantsEzetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mg
Percentage of Participants Who Experience at Least 1 Adverse Event (AE)72.876.2
PrimaryPercentage of Participants Who Had Study Drug Discontinued Due to an AE

An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who had study drug discontinued due to an AE was summarized.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Study Drug Discontinued Due to an AE
Percentage of ParticipantsEzetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mg
Percentage of Participants Who Had Study Drug Discontinued Due to an AE0.90.0
SecondaryPercentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Blood was collected at baseline (predose) and after 52 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by beta quantification ultracentrifugation. The percentage change from baseline at Week 52 was summarized.

Time frame:
Baseline (predose) and Week 52
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Percentage changeEzetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mg
Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)-33.8 (-36.9 to -30.8)-23.9 (-29.1 to -18.6)

Adverse events

Collected over Up to 2 weeks post last dose of study drug (up to 54 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe 10 mg + Rosuvastatin 2.5 mg0/114 (0%)2/114 (1.8%)53/114 (46.5%)
Ezetimibe 10 mg + Rosuvastatin 5.0 mg0/21 (0%)1/21 (4.8%)13/21 (61.9%)
Most frequent serious events
Most frequent serious events
EventEzetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mg
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1141/21
Intestinal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1140/21
Anxiety disorderPsychiatric disorders1/1140/21
Most frequent other events
Most frequent other events
EventEzetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mg
NasopharyngitisInfections and infestations41/1148/21
RhinitisInfections and infestations1/1142/21
ContusionInjury, poisoning and procedural complications2/1142/21
Liver function test abnormalInvestigations3/1142/21
Type 2 diabetes mellitusMetabolism and nutrition disorders3/1142/21
Back painMusculoskeletal and connective tissue disorders9/1141/21
GastroenteritisInfections and infestations8/1141/21

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ezetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mgTotal
Mean58.2 ± 10.852.4 ± 13.357.3 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mgTotal
Female61970
Male531265
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ezetimibe 10 mg + Rosuvastatin 2.5 mgEzetimibe 10 mg + Rosuvastatin 5.0 mgTotal
Hispanic or Latino000
Not Hispanic or Latino11421135
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Teramoto T, Yokote K, Nishida C, Oshima N, Takase T. A Phase III Open-label clinical trial to assess the long-term safety of ezetimibe and rosuvastatin combination therapy in Japanese patients with hypercholesterolemia. J Clin Therapeut Med. 2018;34(11):765-82. (in Japanese) https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2018&vo=34&issue=11

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Dec 2017, 18 months.

Results were first posted in Dec 2018, 11 months after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2016
First posted
Apr 22, 2016
StartActual
May 18, 2016
Primary completionActual
Dec 11, 2017
CompletionActual
Dec 11, 2017
Results first posted
Dec 4, 2018
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02748057
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 22, 2016
Start date
May 18, 2016
Primary completion
Dec 11, 2017
Completion
Dec 11, 2017
Results posted
Dec 4, 2018
Last update
May 16, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Rosuvastatin

Start the discussion